Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GLPG-5201 by Galapagos for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Data Insights
GLPG-5201 by Galapagos for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...